Form 8-K CYTRX CORP For: Apr 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500, Dow rise on Mideast deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
CytRx (CYTR) Issues Update on Ongoing Aldoxorubicin Phase 2b Studies
May 4, 2015 9:04 AM EDTCytRx (NASDAQ: CYTR) announced an interim analysis from its two ongoing phase 1b aldoxorubicin combination studies pairing aldoxorubicin with either gemcitabine or ifosfamide. Both studies combine standard doses of gemcitabine or ifosfamide with escalating doses of aldoxorubicin. The combinations appear to be well tolerated, and even at the lowest dose level of aldoxorubicin (170 mg/m2), impressive tumor responses have been observed so far in patients with bone cancer (osteosarcoma) and a variety of soft tissue sarcomas. As such, aldoxorubicin has the potential when used in combination with other cancer agents to become an important new... More
CytRx (CYTR) Tops Q1 EPS by 52c
May 1, 2015 6:06 AM EDTCytRx (NASDAQ: CYTR) reported Q1 EPS of $0.31, $0.52 better than the analyst estimate of ($0.21).
CytRx recently appointed two new independent members to its Board of Directors. Effective April 30, 2015, Eric J. Selter, J.D. joined the Board and will serve as... More
